U.S. markets closed

PROCEPT BioRobotics Corporation (PRCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
42.04+3.67 (+9.56%)
At close: 04:00PM EDT
41.26 -0.78 (-1.86%)
After hours: 06:07PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close38.37
Bid35.00 x 800
Ask46.00 x 1200
Day's Range35.02 - 42.09
52 Week Range15.38 - 47.73
Avg. Volume539,806
Market Cap1.857B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.45
Earnings DateAug 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PRCT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PROCEPT BioRobotics Corporation
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
    Fair Value
    Economic Moat
    7 days agoMorningstar
View more
  • Motley Fool

    PROCEPT BioRobotics Corporation (PRCT) Q2 2022 Earnings Call Transcript

    Image source: The Motley Fool. PROCEPT BioRobotics Corporation (NASDAQ: PRCT)Q2 2022 Earnings CallAug 04, 2022, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to PROCEPT BioRobotics second quarter earnings conference call.

  • GlobeNewswire

    PROCEPT BioRobotics Reports Second Quarter 2022 Financial Results and Increases 2022 Revenue Guidance

    REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2022. Recent Highlights Total Revenue of $16.7 million for the second quarter of 2022, an increase of 97% compared to the prior year periodU.S. system and rental revenue of $8.5 million for th

  • GlobeNewswire

    PROCEPT BioRobotics to Report Second Quarter 2022 Financial Results on August 4, 2022

    REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter 2022 after market close on Thursday, August 4, 2022. The company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in list